Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A humanoid robot is being used at NDORMS in an attempt to grow tendon tissue for repairing shoulder injuries.

The humanoid robotic bioreactor at NDORMS © David Fisher

For more than 20 years, it has been possible to grow and stretch tissue cells outside of the human body using dynamic bioreactors; systems that control the conditions necessary for maintaining and stimulating living cells and tissues, while involving external mechanical stresses. However, it has still not been possible to produce tendon tissues of high enough quality to work successfully in human grafts.

An important limitation is in the method of mechanically stimulating the cells as Pierre-Alexis Mouthuy, lead author of the study explained. "We're far away from fully functional tendon tissue grafts, and this is partially because we're not providing the complexity of mechanical stresses that cells would experience in a human shoulder," he said. "Existing evidence suggests that delivering advanced physiologically-relevant mechanical cues, or realistic movement of the shoulder up, down, back and forward, with the cells being pushed, pulled, compressed and stretched, is important to mature the tissue properly."

Most current bioreactor systems are only able to deliver unidirectional stretching to the cells, so Pierre and the team from NDORMS looked to real-size musculoskeletal (MSK) humanoid robots as a possible solution to provide physiological stresses, i.e. multidirectional ones. MSK humanoid robots aim to replicate the human musculoskeletal system by mimicking the structure and mechanics of muscles, tendons and bones.

The flexible bioreactor chamber is subjected to repeated abduction-adduction exercises.The flexible bioreactor chamber is subjected to repeated abduction-adduction exercises.

Their paper, published in Communications Engineering, explains how they firstly designed a flexible bioreactor chamber. Inside the chamber, cells were grown on stretchy synthetic scaffolds while being perfused with culture medium (providing them with oxygen and nutrients). On a daily basis, the chambers were positioned on the robotic arm and were subjected to repeated abduction-adduction exercises to replicate some of the forces and movements that they would undergo in a real tendon.

Pierre and his team hope that, in the future, lab grown tendon grafts can be used to improve repair outcomes in patients. "Now that we've demonstrated the feasibility of a humanoid bioreactor approach, we can explore the possibilities of this new platform and see if providing these more physiologically relevant mechanical stresses can really help to improve the quality of engineered tendon grafts."

See the robotic bioreactor in action in this Nature video.

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.